The third annual meeting of the PrIMAVeRa project took place on 07-08 November 2024 in Seville, Spain. Approximately 35 participants attended the meeting, both in person and online.
November 2024
The meeting highlighted the progress made during the third project year and included dynamic panel discussions on model development and data access and limitations in epidemiological data availability. Participants also outlined future plans and priorities.
Aiming to address the urgent challenge of antimicrobial resistance (AMR), PrIMAVeRa partners are developing an open-source, web-based platform. This tool will integrate an epidemiological repository with mathematical modelling to help health authorities and policymakers prioritise the most promising vaccines and monoclonal antibodies (mAbs).
During the meeting, the Consortium presented the advancements from the third project year and outlined next steps. Progress included model development, data acquisition, and the initiation of work packages to refine and evaluate the models. These efforts aim to ensure sustainability of the project’s outputs. Work package leaders and contributors were able to align on goals and activities that will keep the momentum going into the fourth year of the project.
The Consortium expends its gratitude to the external experts who enriched the scientific discussions, including:
Dr Tek-Ang Lim, Scientific Officer from the Innovative Health Initiative (IHI), who presented on the upcoming mid-term review and provided guidance on periodic reporting and communications.
Prof Richard White of the London School of Hygiene and Tropical Medicine, and newest member of the PrIMAVeRa SAC, who delivered a presentation titled “Data, modelling and innovation to support the development and implementation of new TB vaccines”.
Dr Mateusz Hasso-Agopsowicz: Technical Officer at World Health Organisation, and member of the PrIMAVeRa SAC, who provided valuable scientific feedback at the conclusion of the meeting.
The PrIMAVeRa consortium celebrates this milestone in project progress during World Antimicrobial Awareness Week 2024 (WAAW), and looks forward to continued advancements in the coming years.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
Comments